[CML] Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia-Comparison with historic experience.Rob [CML] Regatta incorporates large sailboats and Duffy boats to benefit cancer researchRob
临床试验结果表明,接受TKI治疗获得深度分子学反应持续超过2年的CML患者,有可能实现无治疗缓解(Treatment-freeremission,TFR),因此,CML逐渐成为一种可长期生存的慢性疾病。正因为深度而持久的分子学反应给CML患者带来了显著被延长的无事件生存期(Eventfreesurvival,EFS)、无进展生存期(Progressionfreesurvival,PFS)和总生存...
[4]Jain P, Kantarjian HM, Ghorab A, et al. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients. Cancer. 2017.15;123(22):4391-4402. doi: 10.1002/cncr.30864. [5]Predicting Earl...
该研究正式发表于2014年9月28日 《白血病》 杂志上(Leukemia. 2014 Oct;28(10):1988-92)。 Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in c...
CML治疗解析 慢性髓性白血病－CML 又称为：慢性粒细胞白血病，是白血病的一种，属于恶性肿瘤 病因与体内出现染色体突变有关－－出现费城（Ph＋）染色体 特征:是骨髓中髄细胞恶变产生大量异常粒细胞的一种疾病－－白细胞升高 CML的细胞遗传学异常：费城染色体 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17...
(+)CML各期的一线治疗药物各期的一线治疗药物 新药的发展:新药的发展:AMN107AMN107,,DasatinibDasatinib···7CMLCMLChronicPhaseCMLSurvivalbyTherapyType0%10%20%30%40%50%60%70%80%90%100%Year1Year4Year7Year10Year13Year16Year19PercentofPatientsAliveBMTIFNGLIVECOTHERallCMLexpected8CMLCML 君,已阅读到文...
图1 Treatment-free survival in the TFR phase 56例患者重新使用尼洛替尼进行治疗,截止到96周时52例(93%)重新达到MR4 或MR4.5 的标准。实际上重新使用尼洛替尼的12周或13.1周后,就有超过50%的患者分别达到MR4 或MR4.5 的标准(图2)。其余未达标的4例患者中,2例仍然继续接受治疗,另外2例脱落。
Tyrosine kinase inhibitors (TKI) have moderately improved survival in BC, but a median survival of less than 1 year is still unsatisfactory. Earlier recognition of end-phase CML and early treatment intensification might improve outcome. High-risk additional chromosomal abnormalities and somatic mutations...
More than two-thirds of patients with chronic phase CML achieve long-term control of the disease with TKIs. Although TKIs have not been proven to cure CML, people who have an excellent response to TKI therapy have expectations for survival that are similar to age-matched individuals without CML...
#50 Predictive Factors for Overall Survival in Chronic Myeloid Leukemia Patients: An Analysis By the Gimema Cml Italian Study 从2013年1月至2020年6月,来自GIMEMA CML意大利研究纳入1206例CML患者,服用伊马替尼和2代TKI的分别为608和598例,伊马替尼组患者年龄和Charlson评分(合并症指数)偏高。中位随访24.7个...